Methcathinone (mCAT) is a phenylisopropylamine which is increasingly abused in the Midwest and across this country due to its potent stimulant properties and the ease with which it is synthesized. Because of its emerging popularity, mCAT was recently classified as a Schedule I drug. Although little research on mCAT has been conducted, its short-term intoxication and severe addiction patterns have been compared to crack cocaine or methamphetamine. We recently reported that single and multiple mCAT administrations caused neurochemical deficits in extrapyramidal and limbic dopaminergic and serotonergic systems as long as 72 h after treatment. Because of these observations, we propose that mCAT exerts profound short- and long-term effects on extrapyramidal and limbic monoaminergic systems and has significant neurotoxic potential. This hypothesis will be tested by achieving the following Specific Aims: A. Identify the short and long-term monoaminergic effects of a single mCAT administration. This will be achieved by [i] assessing with microdialysis the effects of mCAT on the release of monoamines, [ii] determining he persistence of mCAT-induced neurochemical changes in monoaminergic systems after a single administration, [iii] evaluating the role of hyperthermia in the monoamine responses to mCAT, [iv] determining the effects of mCAT on free radical formation and [v] monitoring the presence of mCAT in the brain for 24 h after a single injection. B. Identify long-term consequences of multiple administrations of mCAT on monoaminergic systems. This will be achieved by [i] measuring monoaminergic effects of multiple mCAT administrations up to 30 d after treatment, [ii] identifying factors which are responsible for mediating the long-term changes in the monoaminergic systems after multiple mCAT administrations. C. Compare monoaminergic responses to mCAT with those caused by its naturally occurring (found in the Chat plant) demethylated analog, and possible active metabolite, cathinone. The findings from these studies will help (1) educate current and future users about the risks of mCAT abuse, (2) identify appropriate therapeutic strategies for managing mCAT-induced toxicities, and (3) provide insight to the properties of phenylisopropylamines which make them toxic to either or both the serotonergic and dopaminergic systems.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004222-14
Application #
2897715
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Lin, Geraline
Project Start
1986-09-01
Project End
2000-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Vieira-Brock, Paula L; Andrenyak, David M; Nielsen, Shannon M et al. (2013) Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma. Nicotine Tob Res 15:1839-48
McFadden, Lisa M; Stout, Kristen A; Vieira-Brock, Paula L et al. (2012) Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 66:240-5
McFadden, Lisa M; Hunt, Madison M; Vieira-Brock, Paula L et al. (2012) Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug Alcohol Depend 126:87-94
McFadden, Lisa M; Hadlock, Greg C; Allen, Scott C et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303
German, Christopher L; Hanson, Glen R; Fleckenstein, Annette E (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288-97
Hanson, G R; Hoonakker, A J; Alburges, M E et al. (2012) Response of limbic neurotensin systems to methamphetamine self-administration. Neuroscience 203:99-107
Hadlock, Gregory C; Webb, Katy M; McFadden, Lisa M et al. (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530-6
Ellis, Jonathan D; German, Christopher L; Birdsall, Elisabeth et al. (2011) Ephedrine decreases vesicular monoamine transporter-2 function. Synapse 65:449-51
McFadden, Lisa M; Hoonakker, Amanda J; Vieira-Brock, Paula L et al. (2011) Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse 65:771-7
Hadlock, Gregory C; Nelson, Chad C; Baucum 2nd, Anthony J et al. (2011) Ex vivo identification of protein-protein interactions involving the dopamine transporter. J Neurosci Methods 196:303-7

Showing the most recent 10 out of 101 publications